Close

RedHill Biopharma (RDHL) Completes BEKINDA 12 mg PK Study; IND Submitted to FDA

February 11, 2016 9:01 AM EST Send to a Friend
RedHill Biopharma Ltd. (NASDAQ: RDHL) announced the successful completion of a first-in-man pharmacokinetic (PK) study of BEKINDA 12 mg formulation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login